PRECIGEN, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
PRECIGEN, INC. (PGEN) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $36.87 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-03-01
- PRECIGEN, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2018-12-31 was $0.00.
- PRECIGEN, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2018-09-30 was $36.87M.
- PRECIGEN, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $36.87M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $36.87M derived: sum of 2 quarters · filed 2021-03-01 | $36.87M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $36.87M 10-Q · filed 2019-11-12 | $36.87M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |